Literature DB >> 10482266

Regulation of dopaminergic activity in early Parkinson's disease.

J Tedroff1, A Ekesbo, E Rydin, B Långström, G Hagberg.   

Abstract

Parkinson's disease (PD) is characterized by an uneven and progressive loss of nigrostriatal dopaminergic neurons. It is hypothesized that the physiological basis for the therapeutic response in early stages of PD is the ability for the partially and unevenly denervated dopaminergic system to restore and normalize dopaminergic influence in functionally segregated subregions of the basal ganglia. To investigate this hypothesis, patients with early and uncomplicated PD were investigated with positron emission tomography by using a two-tracer protocol yielding a measure of dopamine transporter-corrected dopamine synthesis capacity. Compared with controls, patients with PD exhibited a considerable increase in dopamine transporter-corrected dopamine synthesis capacity. The increase showed an inverse dependence on the structural integrity in as much as the highest rate was measured in the most denervated region, the dorsal part of putamen (198% of control value). A therapeutic challenge with antiparkinsonian medication state-dependently decreased dopaminergic activity. Thus, it is demonstrated that dopaminergic degeneration in PD is accompanied by a conspicuous acceleration of presynaptic dopaminergic activity, which is state-dependently down-regulated by dopaminomimetic treatment. It is suggested that homeostatic mechanisms acting to maintain congruity within the dopaminergic system are functionally intact in early PD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482266

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  6 in total

1.  Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.

Authors:  Kirk A Frey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-22       Impact factor: 9.236

2.  18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages.

Authors:  Jian Wang; Cuan-Tao Zuo; Yu-Ping Jiang; Yi-Hui Guan; Zheng-Ping Chen; Jing-De Xiang; Li-Qin Yang; Zheng-Tong Ding; Jian-Jun Wu; Hui-Lin Su
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

Review 3.  Vesicular integrity in Parkinson's disease.

Authors:  Shawn P Alter; Gina M Lenzi; Alison I Bernstein; Gary W Miller
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

4.  No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.

Authors:  LinLin Tian; Morvarid Karimi; Susan K Loftin; Chris A Brown; HuChuan Xia; JinBin Xu; Robert H Mach; Joel S Perlmutter
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

5.  Correlative (99m)tc-labeled tropane derivative single photon emission computer tomography and clinical assessment in the staging of Parkinson disease.

Authors:  Ajit S Shinto; Joppy Antony; Koramadai Kamaleshwaran; Krishnan Vijayan; Arul Selvan; Aruna Korde; Mythili Kameshwaran; Grace Samuel
Journal:  World J Nucl Med       Date:  2014-09

6.  Parkinson's disease laterality: a 11C-PE2I PET imaging study.

Authors:  Andreas-Antonios Roussakis; Zhou Zeng; Nicholas P Lao-Kaim; Antonio Martin-Bastida; Paola Piccini
Journal:  J Neurol       Date:  2020-09-02       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.